Antimicrobial prescribing: delafloxacin for community-acquired pneumonia Evidence Summary [ES37], NICE (published 10th August 2021)
Review of delafloxacin, a fluoroquinolone antibiotic available as an injection or tablet, covers the strengths and limitations of the efficacy and safety data from the pivotal RCT, where it was found to be non-inferior to moxifloxacin for community-acquired bacterial pneumonia (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 12, 2021 Category: Consumer Health News Source Type: news

Asymptomatic adults may be reservoirs of Streptococcus pneumoniae
(Instituto de Tecnologia Qu í mica e Biol ó gica Ant ó nio Xavier da Universidade NOVA de Lisboa ITQB NOVA) In Europe, S. pneumoniae is the most common cause of community-acquired bacterial pneumonia in adults. Still, very little is known about its colonization within this age group. A team of researchers from ITQB NOVA has now taken a crucial step to clarify the dynamics of carriage of this bacterium in adults. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 5, 2021 Category: Infectious Diseases Source Type: news

Paratek Pharmaceuticals Announces FDA Approval of Nuzyra (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Rates of Macrolide Resistance in S. pneumoniae High Across the U.S.
Clinicians should consider alternatives to macrolide monotherapy as empiric therapy for suspected community - acquired bacterial pneumonia (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 17, 2021 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news

Online COVID-19 Symptom Checkers May Not Catch Severe Illnesses Online COVID-19 Symptom Checkers May Not Catch Severe Illnesses
Digital COVID-19 symptom checkers in the US and the UK may fail to identify severe COVID-19 and other serious illnesses such as bacterial pneumonia or sepsis, according to a group of public health researchers.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - March 12, 2021 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

New study explains important cause of fatal influenza
(Karolinska Institutet) It is largely unknown why influenza infections lead to an increased risk of bacterial pneumonia. Researchers at Karolinska Institutet in Sweden have now described important findings leading to so-called superinfections, which claim many lives around the world every year. The study is published in the journalPNAS,Proceedings of the National Academy of Sciences, and can also contribute to research on COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 25, 2020 Category: Infectious Diseases Source Type: news

Genetic analysis system yields new insights into bacterial pneumonia
(University of California - Santa Cruz) A team of infectious disease researchers has developed a new method to identify virulence genes in Streptococcus pneumoniae, the leading cause of bacterial pneumonia. Using this technique in a mouse model of pneumonia, they were able to gain new insights into the progression of the disease and its interaction with the flu virus. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 28, 2020 Category: Infectious Diseases Source Type: news

Uganda: Acholi Health Centres Hit By Drug Shortage
[Monitor] Living four kilometres off the neighbourhood of Ongako Health Centre III in Ongako Sub-county, Omoro District, Ms Ritah Arac, arrives with her 7-year-old son, who has been ill for a week.An hour later, her son is diagnosed with bacterial pneumonia. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 7, 2020 Category: African Health Source Type: news

FDA Approves Fetroja (cefiderocol) for the Treatment of Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
OSAKA, Japan& FLORHAM PARK, N.J.--(BUSINESS WIRE) September 28, 2020 --Shionogi& Co., Ltd. (hereafter“Shionogi”) today announces that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 28, 2020 Category: Drugs & Pharmacology Source Type: news

Ontario health-care worker returns home six months after testing positive for COVID-19
Six months ago, cross-border health-care worker Torry Robertson of LaSalle, Ont., contracted COVID-19 — leading to renal failure, a super bug, bacterial pneumonia and almost 40 days connected to a ventilator. But Friday, he was finally given the green light to go home, with neighbours, friends and family members cheering him on. (Source: CBC | Health)
Source: CBC | Health - September 19, 2020 Category: Consumer Health News Tags: News/Canada/Windsor Source Type: news

Recarbrio Effective for Hospital-Acquired Bacterial Pneumonia Recarbrio Effective for Hospital-Acquired Bacterial Pneumonia
Recarbrio is noninferior to piperacillin/tazobactam for treating adults with hospital-acquired or ventilator-associated bacterial pneumonia, according to results from the RESTORE-IMI 2 trial.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - August 26, 2020 Category: Intensive Care Tags: Pulmonary Medicine News Source Type: news

Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Developing Drugs for Treatment
Clinical / Antimicrobial (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 24, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Merck ’s Recarbrio (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
KENILWORTH, N.J.--(BUSINESS WIRE) June 5, 2020 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 5, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Antibiotic to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
The FDA has approved Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 4, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news